Gene Therapy in Ophthalmology Market is segmented By Indication (Inherited Retinal Diseases, Acquired Retinal Diseases), By Vector Type (Adeno-associated Virus (AAV), Len ....
Market Size in USD
CAGR25.2%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 25.2% |
Market Concentration | High |
Major Players | Johnson & Johnson Innovative Medicine, MeiraGTx, Beacon Therapeutics, Nanoscope Therapeutics, GenSight Biologics |
The gene therapy in ophthalmology market is estimated to be valued at USD 1.2 Bn in 2024 and is expected to reach USD 5.8 Bn by 2031, growing at a compound annual growth rate (CAGR) of 25.2% from 2024 to 2031. There is a rising trend seen in gene therapy to treat ophthalmic disorders. Manufacturers are involved in research and development of novel gene therapy products for ophthalmic conditions like age-related macular degeneration which has high prevalence rate.